162 related articles for article (PubMed ID: 38621830)
1. Harnessing Antitumor Immunity in Ovarian Cancer.
Kurnit KC; Odunsi K
Cold Spring Harb Perspect Med; 2024 Apr; ():. PubMed ID: 38621830
[TBL] [Abstract][Full Text] [Related]
2. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
3. New Approaches for Immune Directed Treatment for Ovarian Cancer.
Hardwick N; Frankel PH; Cristea M
Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
[TBL] [Abstract][Full Text] [Related]
4. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma.
Liu P; Chen R; Zhang X; Fu R; Tao L; Jia W
BMC Genomics; 2022 Jan; 23(1):51. PubMed ID: 35026984
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in ovarian cancer.
Odunsi K
Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific active immunotherapy for ovarian cancer.
Paijens ST; Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; de Bruyn M; Nijman HW
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD007287. PubMed ID: 30199097
[TBL] [Abstract][Full Text] [Related]
7. Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.
Russell S; Lim F; Peters PN; Wardell SE; Whitaker R; Chang CY; Previs RA; McDonnell DP
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077756
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer.
Cao K; Zhang G; Yang M; Wang Y; He M; Zhang C; Huang Y; Lu J; Liu H
Cancer Res; 2023 Jul; 83(13):2171-2186. PubMed ID: 37172314
[TBL] [Abstract][Full Text] [Related]
9. Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.
Rajtak A; Ostrowska-Leśko M; Żak K; Tarkowski R; Kotarski J; Okła K
Front Immunol; 2022; 13():1018256. PubMed ID: 36439144
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
Lo CS; Sanii S; Kroeger DR; Milne K; Talhouk A; Chiu DS; Rahimi K; Shaw PA; Clarke BA; Nelson BH
Clin Cancer Res; 2017 Feb; 23(4):925-934. PubMed ID: 27601594
[No Abstract] [Full Text] [Related]
13. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
14. The immunotherapy of patients with ovarian cancer.
Hwu P; Freedman RS
J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
[TBL] [Abstract][Full Text] [Related]
15. Immunity and immune suppression in human ovarian cancer.
Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
[TBL] [Abstract][Full Text] [Related]
16. STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?
Huvila J; Cochrane DR; Ta M; Chow C; Greening K; Leung S; Karnezis AN; DiFeo A; Huntsman DG
J Pathol Clin Res; 2021 Nov; 7(6):548-555. PubMed ID: 34138519
[TBL] [Abstract][Full Text] [Related]
17. Harnessing Pyroptosis for Cancer Immunotherapy.
Bourne CM; Taabazuing CY
Cells; 2024 Feb; 13(4):. PubMed ID: 38391959
[TBL] [Abstract][Full Text] [Related]
18. Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.
Yu P; Wang Y; Yuan D; Sun Y; Qin S; Li T
Front Immunol; 2023; 14():1276694. PubMed ID: 37936692
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment.
Drakes ML; Stiff PJ
Cancers (Basel); 2018 Sep; 10(9):. PubMed ID: 30200478
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of the immune microenvironment in ovarian cancer patients.
Yang L; Wang S; Zhang Q; Pan Y; Lv Y; Chen X; Zuo Y; Hao D
Mol Omics; 2018 Oct; 14(5):341-351. PubMed ID: 30129640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]